Lilly introduces Zepbound vials at 50% discount

US pharma major Eli Lilly (NYSE: LLY) yesterday announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are now available for self-pay for patients in the USA with an on-label prescription, significantly expanding the supply of the weight loss treatment in response to high demand.

Lilly says the single-dose vials are priced at a 50% or greater discount compared to the list price of all other incretin (GLP-1) medicines for obesity. Zepbound is typically sold in an injector pen. This new option helps millions of adults with obesity access the medicine they need, including those not eligible for the Zepbound savings card program, those without employer coverage, and those who need to self-pay outside of insurance.

A four-week supply of the 2.5mg Zepbound single-dose vial is $399 ($99.75 per vial), and a four-week supply of the 5mg dose is $549 ($137.25 per vial) – which Lilly claims is less than half the list price of other incretin medicines for obesity and in line with the Zepbound savings program for non-covered individual